

[Artesunate - sulfadoxine + pyrimethamine](#)

Essential medicine status

Section:

[6. Anti-infective medicines](#) [6.5. Antiprotozoal medicines](#) [6.5.3. Antimalarial medicines](#) [6.5.3.1. Antimalarial medicines > Medicines for curative treatment](#)

ATC codes: [P01BF09](#)

EMLc

Indication

Malaria due to Plasmodium falciparum ICD11 code: [1F40](#)

INN

Artesunate + sulfadoxine + pyrimethamine

Medicine type

Chemical agent

List type

Core

Formulations

Oral > Solid > tablet: 50 mg [3] + 500 mg + 25 mg [1] in copackage (scored)

EML status history

First added in 2025 ([TRS 1064](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

The recommendation is for this specific medicine

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Artesunate - sulfadoxine + pyrimethamine](#)

Summary of evidence and Expert Committee recommendations



Following the review of the age appropriateness of formulations on the EMLc, the Expert Committee recommended: - the addition of a co-packaged formulation of artesunate and sulfadoxine + pyrimethamine on the EML and EMLc, noting that this presentation would replace the separate listings of artesunate 50 mg tablets and sulfadoxine + pyrimethamine 500 mg + 25 mg tablets, which are recommended for deletion.